Efficacy and Safety Study of Neu2000KWL for Acute Ischemic Stroke Patients Within 6 Hours of Onset

Phase 2

Completed

• Conditions: Stroke; Cerebral Infarction
• Interventions: Drug: Neu2000KWL; Drug: Placebos

• Registration Number: NCT04486430
• Lead Sponsor: Beijing Tiantan Hospital

Brief Summary

The purpose of the study is to explore safety and efficacy of Salfaprodil administration for patients with acute ischemic stroke within 6 hours of onset.

Detailed Description

The present study is to investigate safety and efficacy of Neu2000, a multi-target neuroprotectant acting as a moderate NR2B-selective NMDA receptor antagonist and potent antioxidant, in acute ischemic stroke patients within 6 hours of onset. Compared to NMDA antagonists or antioxidants, improved efficacy and therapeutic time window of Neu2000 have been well documented in four animal models of stroke. Notable Safety of Neu2000 has been demonstrated in 168 human subjects conducted in the US and China as well as animals.

In the present phase II study, patients with acute ischemic stroke within 6 hours of onset would be assigned randomly to one of four groups as follows:

* Group A receiving 2.75g Neu2000KWL for 5 days

* Group B receiving 5.25g Neu2000KWL for 5 days

* Group C receiving 6.00g Neu2000KWL for 5 days

* Group D receiving placebo for 5 days

Patients will receive intravenous infusion of the clinical study drug twice a day at 12±1 hour intervals for 5 days.

Study Timeline

• Status Verified: 2017-01
• Study Start: 2017-03-02
• Primary Completion: 2019-06-12
• Study Completion: 2019-12-13
• Study First Submitted: 2020-07-22
• Study First Submitted QC: 2020-07-23
• Last Update Submitted: 2020-07-23
• Study First Posted: 2020-07-24
• Last Update Posted: 2020-07-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 236

Inclusion Criteria

1. patients aged between 35 and 75 years;
2. acute ischemic stroke patients in internal carotid artery system within 6 hours of onset;
3. patients with NIHSS scores of 4 to 22 and limb weakness including motor arm or motor leg score ≥2 of NIHSS;
4. patients within 6 hours of onset or the last time known to be symptom free (within 6 hours of the start of sleep for ischemic stroke patients with onset during sleep), and who receive a CT test before the clinical study;
5. Informed consent should be signed from the patient or patient's legally authorized representative;
6. patients with premorbid mRS score of 0~1;
7. patients with no history of myocardial infarction within last 3 months;
8. patients with no heart, liver, kidney and lung function deficit;
9. patients with no hemorrhagic diseases within last 3 months;
10. patients with no haematological diseases.

Exclusion Criteria

1. Any contraindication to CT and MRI (e.g., metal implants such as pacemakers, claustrophobia);
2. Stroke caused by posterior circulation ischemia, or transient ischemic attack (TIA);
3. Acute intracranial hemorrhage, intracranial neoplasm, cobweb hemorrhage, cerebritis or other non-acute ischemic stroke and cerebral arteriovenous malformation;
4. Endovascular treatment within 6 hours of onset, such as mechanical embolectomy, stent angioplasty or arteriovenous bridge treatment;
5. Pregnant or lactating women. Note: the pregnancy test of fertile women must be negative before randomization into groups, and female patients must take appropriate contraceptive methods at least for 3 weeks prior to the clinical study and over the next 7 days following the last injection of test drugs;
6. Pre-existing medical, neurologic, or psychiatric diseases that would confound the neurologic, functional, or imaging evaluations, such as persistent deficit from previous ischemic stroke;
7. Malignant tumor or other critical disease;
8. Patients with a history of epilepsy or undergoing seizure on onset of the ischemic stroke
9. A history of intracranial hemorrhage;
10. Patients with low blood pressure, or showing blood pressure lower than 90/60mmHg in three consecutive times after admission;
11. A history of severe injury and surgical operation within the last 3 months;
12. Consciousness disorder as defined as "NIHSS Ia score ≥2 ";
13. Complete atrioventricular block bradycardia;
14. Cardiac function rating above II level according to the New York heart association (NYHA) grade of cardiac function, history of congestive heart failure (CHF);
15. With primary liver and kidney disease, AST or ALT 2 times greater than upper normal limit, serum creatinine >2.0 mg/dL or >176.8 µmol/L;
16. International normalized ratio (INR) > 1.7 or current use of oral anticoagulants, except aspirin, clopidogrel, subcutaneous heparin or warfarin;
17. With bleeding tendency disease (such as hemophilia), partial thromboplastin time (PTT) > 3 ×the upper limit of normal;
18. A history of, or known current problems with, drug or alcohol abuse;
19. A irritability experience of the study drugs or drugs with similar chemical structures;
20. Participation in other clinical trials or studies before this study within the last 3 months;
21. Researchers consider that patients don't suit for the study.
22. Hepatitis B and C, HIV-positive patients

Imaging exclusion criteria:

1. patients with high density lesions associated with haemorrhage on CT scan after admission;
2. patients with significant lower density lesions of 1/3 middle cerebral artery on CT scan after admission;
3. patients with intracranial parenchymal tumors on CT scan after admission.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Neu2000KWL 2750mg dose group	Neu2000KWL	Low dose group
Neu2000KWL 5250mg dose group	Neu2000KWL	Middle dose group
Neu2000KWL 6000mg dose group	Neu2000KWL	High dose group
Placebo	Placebos	Placebo

Primary Outcome Measures

Name	Time	Method
The ratio of patients with NIHSS score of 0-1 or with reduction of NIHSS score of ≥4 than the baseline on 14 ± 2 day following the first injection.	days:14±2	The ratio of patients with NIHSS score of 0-1 or with reduction of NIHSS score of ≥4 than the baseline on 14 ± 2 day following the first injection.

Secondary Outcome Measures

Name	Time	Method
Change from the baseline in Barthel Index (BI) score on 14 ± 2, 30 ± 2 and 90 ± 7 days following the first injection.	days 14±2, 30±2 and 90±7	Change from the baseline in Barthel Index (BI) score on 14 ± 2, 30 ± 2 and 90 ± 7 days following the first injection.
Change from the baseline in mRS score on 14 ± 2, 30 ± 2 and 90 ± 7 days following the first injection.	days 14±2, 30±2 and 90±7	Change from the baseline in mRS score on 14 ± 2, 30 ± 2 and 90 ± 7 days following the first injection.
Change from the baseline in NIHSS score on 14 ± 2, 30 ± 2 and 90 ± 7 days following the first injection. 1. Change from the baseline in NIHSS score on 14 ± 2, 30 ± 2 and 90 ± 7 days following the first injection.	days 14±2, 30±2 and 90±7	Change from the baseline in NIHSS score on 14 ± 2, 30 ± 2 and 90 ± 7 days following the first injection.

Trial Locations

Locations (1)

Beijing Stroke Association; 🇨🇳 Beijing, Beijing, China